Skip directly to content

Prevenar 13®

Prevenar 13® (13-valent pneumococcal polysaccharide conjugate vaccine) adopts the latest conjugation technology, which induces immune memory, and hence provides long lasting protection with one convenient dose to individuals aged 2 or above1-3. Prevenar13® is included in the Hong Kong Childhood Immunization Programme for children aged below 2 and recommended by HK Centre for Health Protection for elderly aged 65 or above4. Particularly, the elderly with high risk conditions such as. chronic disease patients should receive Prevenar13® as the priority pneumococcal vaccine4. US Centers for Disease Control and Prevention also recommends Prevenar13® for use as a priority shot among elderly aged 65 or above5. Protect yourself and your loved ones - Take Action NOW!

 

Reference:

  1. Pollard AJ, Perrett KP, Beverley PC. Maintaining protection against invasive bacteria with protein–polysaccharide conjugate vaccines. Nature Reviews Immunology. 2009 Mar;9(3):213.
  2. Goldblatt D. Conjugate vaccines. Clinical & Experimental Immunology. 2000 Jan;119(1):1-3.
  3. Prevenar 13®(Pneumococcal polysaccharide conjugate vaccine, 13-valent adsorbed) Prescribing Information. Pfizer Corporation Hong Kong Limited: Version July 2018.
  4. Centre for Health Protection, the Government of the HKSAR. Updated Recommendations on the Use of Pneumococcal Vaccines for High-risk Individuals. Dec 2014. Available at https://www.chp.gov.hk/files/pdf/updated_recommendations_on_the_use_of_pneumococcal_vaccines_for_high-risk_individuals.pdf. Accessed 9 August 2019.
  5. Kobayashi M, Bennett NM, Gierke R, Almendares O, Moore MR, Whitney CG, Pilishvili T. Intervals between PCV13 and PPSV23 vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report. 2015 Sep 4;64(34):944-7.

 

[PP-CPF-HKG-0065] SEP2019